FibroBiologics to Provide Company Update at Upcoming Conferences

HOUSTON, September 14, 2023/PRNewswire/ – FibroBiologics, a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that Pete O’Heeron, Founder/Chief Executive Officer, and Hamid Khoja Ph.D., Chief Scientific Officer, will be giving company presentations at the upcoming Life Science Intelligence (LSI) Europe […]

FibroBiologics Dedicates Laboratory Facility as the Newlin-Linscomb Lab for Cell Therapeutics

HOUSTON, September 12, 2023 /PRNewswire/ – FibroBiologics, a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the dedication of its cutting-edge laboratory facility as the Newlin-Linscomb Lab for Cell Therapeutics, within the University of Houston Innovation Center. “We celebrate the inauguration of […]

FibroBiologics to Present Corporate Update at 2023 BIO International Convention

Clinical-Stage Company Focused on Advancing Fibroblast Cell-Based Therapies for Treatment of Chronic Diseases HOUSTON, June 1, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced that Pete O’Heeron, Founder and Chief Executive Officer, will present a corporate overview next week at the 2023 BIO International […]